Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor

[1]  A. Jaiswal,et al.  NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. , 2006, Biochemical pharmacology.

[2]  G. Ferry,et al.  NRH:quinone reductase 2: an enzyme of surprises and mysteries. , 2005, Biochemical pharmacology.

[3]  Shiuan Chen,et al.  Quinone reductase-mediated nitro-reduction: clinical applications. , 2004, Methods in enzymology.

[4]  A. Sartorelli,et al.  Bioactivation and resistance to mitomycin C. , 2004, Methods in enzymology.

[5]  L. Amzel,et al.  Structure and mechanism of NAD[P]H:quinone acceptor oxidoreductases (NQO). , 2004, Methods in enzymology.

[6]  A. Jaiswal,et al.  Role of GRP58 in mitomycin C-induced DNA cross-linking. , 2003, Cancer research.

[7]  S. McKeown,et al.  Modification of the alkaline Comet assay to allow simultaneous evaluation of mitomycin C-induced DNA cross-link damage and repair of specific DNA sequences in RT4 cells. , 2003, DNA repair.

[8]  K. Danenberg,et al.  Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. , 2001, Clinical Cancer Research.

[9]  T. C. Jenkins,et al.  Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. , 2000, Cancer research.

[10]  A. Jaiswal,et al.  A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C , 2000, British Journal of Cancer.

[11]  A. Jaiswal,et al.  Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. , 1997, Archives of biochemistry and biophysics.

[12]  A. Tomida,et al.  DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. , 1996, Cancer research.

[13]  M. Grever,et al.  Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. , 1996, Journal of the National Cancer Institute.

[14]  A. Jaiswal,et al.  Non‐enzymatic and enzymatic activation of mitomycin C: Identification of a unique cytosolic activity , 1996, International journal of cancer.

[15]  D. Ross,et al.  pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin. , 1993, Molecular pharmacology.

[16]  A. Sartorelli,et al.  Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. , 1993, Cancer research.

[17]  D. Ross,et al.  Bioreductive activation of mitomycin C by DT-diaphorase. , 1992, Biochemistry.

[18]  G. Adams,et al.  The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? , 1992, Biochemical pharmacology.

[19]  G. Powis,et al.  Cytosolic NAD(P)H:(Quinone‐acceptor)oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol , 1990, International journal of cancer.

[20]  N. Bachur,et al.  Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. , 1984, The Journal of biological chemistry.

[21]  W. Szybalski,et al.  A MOLECULAR MECHANISM OF MITOMYCIN ACTION: LINKING OF COMPLEMENTARY DNA STRANDS. , 1963, Proceedings of the National Academy of Sciences of the United States of America.